Latest Action
Referred to the Subcommittee on Health.
6/21/2019 • House
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Introduced in House • 6/20/2019
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (23)
Party Breakdown
Sponsor
Cosponsors (22)
Bill Journey
Originated in the House
Introduced
June 20, 2019
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law